123 related articles for article (PubMed ID: 38867080)
21. Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines.
Kwon YJ; Hurst DR; Steg AD; Yuan K; Vaidya KS; Welch DR; Frost AR
Clin Exp Metastasis; 2011 Jun; 28(5):437-49. PubMed ID: 21442356
[TBL] [Abstract][Full Text] [Related]
22. p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status.
Wang Y; Wang Q; Tang CH; Chen HD; Hu GN; Shao JK; Dong XF; Jin LL; Wang CQ
Medicine (Baltimore); 2021 Mar; 100(10):e25124. PubMed ID: 33725911
[TBL] [Abstract][Full Text] [Related]
23. Hedgehog pathway and GLI1 isoforms in human cancer.
Carpenter RL; Lo HW
Discov Med; 2012 Feb; 13(69):105-13. PubMed ID: 22369969
[TBL] [Abstract][Full Text] [Related]
24. Activated STAT3 Is a Novel Regulator of the
Wright G; Sonavane M; Gassman NR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067421
[TBL] [Abstract][Full Text] [Related]
25. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval.
Prange A; Bokhof B; Polzer P; Tio J; Radke I; Heidinger O; Heindel W; Weigel S
Rofo; 2019 Feb; 191(2):130-136. PubMed ID: 30103233
[TBL] [Abstract][Full Text] [Related]
26. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
28. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.
Colavito SA; Zou MR; Yan Q; Nguyen DX; Stern DF
Breast Cancer Res; 2014 Sep; 16(5):444. PubMed ID: 25252859
[TBL] [Abstract][Full Text] [Related]
29. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-30 Promotes Breast Cancer Growth and Progression.
Airoldi I; Cocco C; Sorrentino C; Angelucci D; Di Meo S; Manzoli L; Esposito S; Ribatti D; Bertolotto M; Iezzi L; Natoli C; Di Carlo E
Cancer Res; 2016 Nov; 76(21):6218-6229. PubMed ID: 27550449
[TBL] [Abstract][Full Text] [Related]
31. Identification, functional characterization, and pathobiological significance of GLI1 isoforms in human cancers.
Carpenter RL; Lo HW
Vitam Horm; 2012; 88():115-40. PubMed ID: 22391302
[TBL] [Abstract][Full Text] [Related]
32. Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data.
You SH; Chae BJ; Eom YH; Yoo TK; Kim YS; Kim JS; Park WC
J Breast Cancer; 2018 Dec; 21(4):415-424. PubMed ID: 30607163
[TBL] [Abstract][Full Text] [Related]
33. STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer.
Conway ME; McDaniel JM; Graham JM; Guillen KP; Oliver PG; Parker SL; Yue P; Turkson J; Buchsbaum DJ; Welm BE; Myers RM; Varley KE
Cancer Res; 2020 Oct; 80(20):4355-4370. PubMed ID: 32816914
[TBL] [Abstract][Full Text] [Related]
34. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
35. Impact of breast cancer subtypes and patterns of metastasis on outcome.
Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
[TBL] [Abstract][Full Text] [Related]
36. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
[TBL] [Abstract][Full Text] [Related]
38. The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex.
Carr RM; Romecin Duran PA; Tolosa EJ; Ma C; Oseini AM; Moser CD; Banini BA; Huang J; Asumda F; Dhanasekaran R; Graham RP; Toruner MD; Safgren SL; Almada LL; Wang S; Patnaik MM; Roberts LR; Fernandez-Zapico ME
J Biol Chem; 2020 Feb; 295(9):2698-2712. PubMed ID: 31988246
[TBL] [Abstract][Full Text] [Related]
39. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients.
Alwan NAS; Tawfeeq FN
Open Access Maced J Med Sci; 2019 Nov; 7(21):3534-3539. PubMed ID: 32010372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
